Product logins

Find logins to all Clarivate products below.


Dry and Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast (G7)

Age-related macular degeneration (AMD) is a late-onset retinal disease that diminishes central visual acuity due to photoreceptor degeneration in the macula leading to vision impairment and blindness. Wet AMD is currently treated with historical mainstays such as off-label Avastin and Eylea, as well as newer entrants to the market including Roche / Chugai’s Vabysmo and Regeneron / Bayer / Santen’s Eylea HD. The wet AMD market will see further fragmentation with the introduction of emerging therapies, that mostly aim to further extend treatment intervals. These include three gene therapies (i.e., Regenxbio / AbbVie’s sura-vec (formerly ABBV-RGX-314), Adverum’s ixo-vec, and 4DMT’s 4D-150), and three long-acting TKIs (i.e., EyePoint Pharmaceutical’s Duravyu, Ocular Therapeutix’s Axpaxli, and Clearside Biomedical’s CLS-AX). By contrast, the management of geographic atrophy (GA) is currently limited to two complement system inhibitors in the United States, Apellis’s Syfovre and Astellas’s Izervay. We expect the launch of J&J Innovative Medicines’ JNJ-1887 in the United States by the end of our forecast and the launch of Izervay in Japan in 2026.

Questions answered

  • How will the wet AMD treatment algorithm change as new products such as Vabysmo and Eylea HD gain traction? To what extent will they capitalize on the need for therapies with longer dosing intervals?
  • How will biosimilars of Eylea impact market dynamics in the different geographies?
  • How receptive are retinal specialists to novel gene therapy approaches and to emerging therapies for wet AMD and GA?
  • What are U.S. retinal specialists’ impressions of novel GA treatments?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents


Related Market Assessment Reports

Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…